CN101466735A - 多发性硬化和/或类风湿性关节炎的治疗 - Google Patents

多发性硬化和/或类风湿性关节炎的治疗 Download PDF

Info

Publication number
CN101466735A
CN101466735A CNA2007800203076A CN200780020307A CN101466735A CN 101466735 A CN101466735 A CN 101466735A CN A2007800203076 A CNA2007800203076 A CN A2007800203076A CN 200780020307 A CN200780020307 A CN 200780020307A CN 101466735 A CN101466735 A CN 101466735A
Authority
CN
China
Prior art keywords
medicament
antibody
treatment
ccr2
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800203076A
Other languages
English (en)
Chinese (zh)
Inventor
M·普林茨
W·布鲁克
A·米尔德纳
M·马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georg August Universitaet Goettingen
Universitätsklinikum Regensburg
Original Assignee
Georg August Universitaet Goettingen
Universitätsklinikum Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg August Universitaet Goettingen, Universitätsklinikum Regensburg filed Critical Georg August Universitaet Goettingen
Publication of CN101466735A publication Critical patent/CN101466735A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800203076A 2006-04-03 2007-04-02 多发性硬化和/或类风湿性关节炎的治疗 Pending CN101466735A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006015341A DE102006015341A1 (de) 2006-04-03 2006-04-03 Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
DE102006015341.3 2006-04-03

Publications (1)

Publication Number Publication Date
CN101466735A true CN101466735A (zh) 2009-06-24

Family

ID=38226352

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800203076A Pending CN101466735A (zh) 2006-04-03 2007-04-02 多发性硬化和/或类风湿性关节炎的治疗

Country Status (8)

Country Link
US (1) US9068002B2 (https=)
EP (2) EP2004692B1 (https=)
JP (1) JP2009532399A (https=)
CN (1) CN101466735A (https=)
AU (1) AU2007236269B2 (https=)
CA (1) CA2648330C (https=)
DE (1) DE102006015341A1 (https=)
WO (1) WO2007115713A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013276991C1 (en) * 2007-08-13 2016-08-11 Takeda Pharmaceutical Company Limited IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
CN110709422B (zh) * 2017-04-19 2023-12-26 马伦戈治疗公司 多特异性分子及其用途
WO2020232127A1 (en) * 2019-05-13 2020-11-19 The Research Foundation For The State University Of New York Compositions and methods to block and bind ccr2 to modulate cellular function
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
MX2024004447A (es) 2021-10-27 2024-05-08 Granite Bio Ag Anticuerpos dirigidos a ccr2.
CN121399160A (zh) 2023-05-29 2026-01-23 花岗岩生物股份公司 靶向ccr2的抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE9600820D0 (sv) 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6723538B2 (en) * 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
JP4398620B2 (ja) * 2000-02-03 2010-01-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
SE0002045D0 (sv) 2000-05-31 2000-05-31 Sahltech Ab New use
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
MXPA06000176A (es) 2003-12-10 2006-06-27 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y sus metodos de uso.

Also Published As

Publication number Publication date
US20090311273A1 (en) 2009-12-17
CA2648330A1 (en) 2007-10-18
JP2009532399A (ja) 2009-09-10
CA2648330C (en) 2015-11-24
EP2004692B1 (de) 2013-07-24
US9068002B2 (en) 2015-06-30
EP2481757A1 (de) 2012-08-01
WO2007115713A1 (de) 2007-10-18
EP2004692A1 (de) 2008-12-24
AU2007236269B2 (en) 2012-09-20
DE102006015341A1 (de) 2007-10-04
AU2007236269A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
US20240350625A1 (en) Combination of il-4/il-13 pathway inhibitors and plasma cell abalation for treating allergy
TWI784988B (zh) 治療發炎症狀的方法
Christensen et al. K/BxN serum-transfer arthritis as a model for human inflammatory arthritis
Chu et al. Interferon‐γ regulates susceptibility to collagen‐induced arthritis through suppression of interleukin‐17
CN111939261B (zh) 以il-4r抑制剂治疗嗜酸性食管炎的方法
AU2007236269B2 (en) Treatment of multiple sclerosis and/or rheumatoid arthritis
JP2009526756A (ja) Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法
CN102988959A (zh) Nkg2d的调节
JP2007537157A (ja) アレルギー性反応に関与する細胞を標的化するための二重特異性抗体、ならびにその組成物および使用
JP5777522B2 (ja) 初期段階の関節リウマチ治療用のｉｌ−３阻害剤
CN112451661A (zh) α-烯醇化酶特异性抗体及其在免疫疾病治疗中的使用方法
AU2005291741B2 (en) Type I interferon blocking agents for prevention and treatment of psoriasis
JP2009532399A5 (https=)
JP7576847B2 (ja) 免疫応答抑制剤
RU2849860C1 (ru) Применение связывающих cxcl13 молекул для лечения повреждения периферических нервов
US11702470B2 (en) Use of CXCL13 binding molecules to promote peripheral nerve regeneration
TW202019482A (zh) Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法
JP2022500387A (ja) Ｍｕｓｋ阻害
Ochs Proinflammatory CD20+ T cells: Their origin and therapeutic depletion in CNS-directed autoimmunity
WO2026008865A1 (en) Products for use in the treatment and prevention of allergy and lung conditions/diseases associated with an allergy or with a pathogen-driven immune response

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090624